Myelodysplastic syndromes: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up (Q55969986)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25185242%20AND%20SRC:MED&resulttype=core&format=json

16 February 2020

title

Myelodysplastic syndromes: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25185242%20AND%20SRC:MED&resulttype=core&format=json

16 February 2020

0 references

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25185242%20AND%20SRC:MED&resulttype=core&format=json

ESMO Guidelines Working Group

16 February 2020

6

object named as

ESMO Guidelines Working Group

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25185242%20AND%20SRC:MED&resulttype=core&format=json

16 February 2020

1

P Fenaux

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25185242%20AND%20SRC:MED&resulttype=core&format=json

16 February 2020

author name string

D Haase

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25185242%20AND%20SRC:MED&resulttype=core&format=json

16 February 2020

G F Sanz

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25185242%20AND%20SRC:MED&resulttype=core&format=json

16 February 2020

C Buske

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25185242%20AND%20SRC:MED&resulttype=core&format=json

16 February 2020

publication date

25 July 2014

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25185242%20AND%20SRC:MED&resulttype=core&format=json

16 February 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25185242%20AND%20SRC:MED&resulttype=core&format=json

16 February 2020

volume

25 Suppl 3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25185242%20AND%20SRC:MED&resulttype=core&format=json

16 February 2020

issue

suppl 3

0 references

page(s)

iii57-69

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25185242%20AND%20SRC:MED&resulttype=core&format=json

Clinical effect of point mutations in myelodysplastic syndromes

16 February 2020

cites work

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU180

Genome-wide aberrant DNA methylation of microRNA host genes in hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU180

Stem and progenitor cells in myelodysplastic syndromes show aberrant stage-specific expansion and harbor genetic and epigenetic alterations

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU180

Aberrant DNA methylation is a dominant mechanism in MDS progression to AML.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU180

The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU180

Revised international prognostic scoring system for myelodysplastic syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU180

Incidence and prevalence of myelodysplastic syndromes: data from the Düsseldorf MDS-registry

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU180

Therapy-related myeloid neoplasms

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU180

Risk of cancer after low doses of ionising radiation: retrospective cohort study in 15 countries

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU180

Risk of myelodysplastic syndromes in people exposed to ionizing radiation: a retrospective cohort study of Nagasaki atomic bomb survivors

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU180

Occupational and environmental risk factors of the myelodysplastic syndromes in the North of France.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU180

Exposure to myelotoxic agents and myelodysplasia: case-control study and correlation with clinicobiological findings.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU180

Definitions and standards in the diagnosis and treatment of the myelodysplastic syndromes: Consensus statements and report from a working conference

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU180

Minimal diagnostic criteria for myelodysplastic syndromes and separation from ICUS and IDUS: update and open questions

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU180

Refinement of the international prognostic scoring system (IPSS) by including LDH as an additional prognostic variable to improve risk assessment in patients with primary myelodysplastic syndromes (MDS).

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU180

Gene silencing by DNA methylation in haematological malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU180

Coalesced multicentric analysis of 2,351 patients with myelodysplastic syndromes indicates an underestimation of poor-risk cytogenetics of myelodysplastic syndromes in the international prognostic scoring system

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU180

Complex, not monosomal, karyotype is the cytogenetic marker of poorest prognosis in patients with primary myelodysplastic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU180

Monosomal karyotype in MDS: explaining the poor prognosis?

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU180

Frequent pathway mutations of splicing machinery in myelodysplasia

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU180

Clinical and biological implications of driver mutations in myelodysplastic syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU180

Myelodysplastic Syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU180

Revised International Prognostic Scoring System (IPSS) predicts survival and leukemic evolution of myelodysplastic syndromes significantly better than IPSS and WHO Prognostic Scoring System: validation by the Gruppo Romano Mielodisplasie Italian Reg

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU180

Diagnosis and treatment of primary myelodysplastic syndromes in adults: recommendations from the European LeukemiaNet

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU180

Clinical relevance of bone marrow fibrosis and CD34-positive cell clusters in primary myelodysplastic syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU180

Comparison of idarubicin + ara-C-, fludarabine + ara-C-, and topotecan + ara-C-based regimens in treatment of newly diagnosed acute myeloid leukemia, refractory anemia with excess blasts in transformation, or refractory anemia with excess blasts

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU180

Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU180

5-azacitidine prolongs overall survival in patients with myelodysplastic syndrome--a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU180

A multivariate analysis of the relationship between response and survival among patients with higher-risk myelodysplastic syndromes treated within azacitidine or conventional care regimens in the randomized AZA-001 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU180

Survival advantage with decitabine versus intensive chemotherapy in patients with higher risk myelodysplastic syndrome: comparison with historical experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU180

Low-dose cytosine arabinoside (LD-AraC) vs LD-AraC plus granulocyte/macrophage colony stimulating factor vs LD-AraC plus Interleukin-3 for myelodysplastic syndrome patients with a high risk of developing acute leukemia: final results of a randomized

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU180

Outcome of high-risk myelodysplastic syndrome after azacitidine treatment failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU180

Comparison of allogeneic stem cell transplantation and non-transplant approaches in elderly patients with advanced myelodysplastic syndrome: optimal statistical approaches and a critical appraisal of clinical results using non-randomized data

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU180

Transplantation for myelodysplastic syndromes 2013.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU180

Retrospective comparison of bone marrow and granulocyte colony-stimulating factor-mobilized peripheral blood progenitor cells for allogeneic stem cell transplantation using HLA identical sibling donors in myelodysplastic syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU180

The lower risk MDS patient at risk of rapid progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU180

Validation of a prognostic model and the impact of mutations in patients with lower-risk myelodysplastic syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU180

Long-term outcome of anemic lower-risk myelodysplastic syndromes without 5q deletion refractory to or relapsing after erythropoiesis-stimulating agents.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU180

Impact of iron overload in myelodysplastic syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU180

Relationship between changes in hemoglobin level and quality of life during chemotherapy in anemic cancer patients receiving epoetin alfa therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU180

Predictive factors of response and survival in myelodysplastic syndrome treated with erythropoietin and G-CSF: the GFM experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU180

Erythropoietin and granulocyte-colony stimulating factor treatment associated with improved survival in myelodysplastic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU180

Treatment of myelodysplastic syndrome patients with erythropoietin with or without granulocyte colony-stimulating factor: results of a prospective randomized phase 3 trial by the Eastern Cooperative Oncology Group (E1996).

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU180

Efficacy of growth factors compared to other therapies for low-risk myelodysplastic syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU180

High-dose darbepoetin alpha in the treatment of anaemia of lower risk myelodysplastic syndrome results of a phase II study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU180

Phase 2, single-arm trial to evaluate the effectiveness of darbepoetin alfa for correcting anaemia in patients with myelodysplastic syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU180

A validated decision model for treating the anaemia of myelodysplastic syndromes with erythropoietin + granulocyte colony-stimulating factor: significant effects on quality of life

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU180

Treatment of myelodysplastic syndromes with 5q deletion before the lenalidomide era; the GFM experience with EPO and thalidomide

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU180

Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU180

A randomized phase 3 study of lenalidomide versus placebo in RBC transfusion-dependent patients with Low-/Intermediate-1-risk myelodysplastic syndromes with del5q.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU180

TP53 mutations in low-risk myelodysplastic syndromes with del(5q) predict disease progression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU180

Antithymocyte globulin (ATG)-based therapy in patients with myelodysplastic syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU180

Factors affecting response and survival in patients with myelodysplasia treated with immunosuppressive therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU180

Further analysis of trials with azacitidine in patients with myelodysplastic syndrome: studies 8421, 8921, and 9221 by the Cancer and Leukemia Group B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU180

Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU180

Phase 2 study of lenalidomide in transfusion-dependent, low-risk, and intermediate-1 risk myelodysplastic syndromes with karyotypes other than deletion 5q.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU180

Lenalidomide in lower-risk myelodysplastic syndromes with karyotypes other than deletion 5q and refractory to erythropoiesis-stimulating agents.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU180

Lenalidomide for treatment of myelodysplastic syndromes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU180

A prognostic score for patients with lower risk myelodysplastic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU180

Phase II study of low-dose interleukin-11 in patients with myelodysplastic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU180

Androgen therapy in myelodysplastic syndromes with thrombocytopenia: a report on 20 cases

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU180

Role of splenectomy in the treatment of myelodysplastic syndromes with peripheral thrombocytopenia: a report on six cases

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU180

Results of a randomized, double-blind study of romiplostim versus placebo in patients with low/intermediate-1-risk myelodysplastic syndrome and thrombocytopenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU180

High response rate and improved exercise capacity and quality of life with a new regimen of darbepoetin alfa with or without filgrastim in lower-risk myelodysplastic syndromes: a phase II study by the GFM.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU180

Value of sequential monitoring of left ventricular ejection fraction in the management of thalassemia major

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU180

Cardiac T2* magnetic resonance for prediction of cardiac complications in thalassemia major

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU180

Prognostic factors and life expectancy in myelodysplastic syndromes classified according to WHO criteria: a basis for clinical decision making.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU180

Evaluation of myocardial iron by magnetic resonance imaging during iron chelation therapy with deferrioxamine: indication of close relation between myocardial iron content and chelatable iron pool.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU180

Does iron chelation therapy improve survival in regularly transfused lower risk MDS patients? A multicenter study by the GFM (Groupe Francophone des Myélodysplasies).

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU180

Prognostic impact of elevated pretransplantation serum ferritin in patients undergoing myeloablative stem cell transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU180

Objectives of iron chelation therapy in myelodysplastic syndromes: more than meets the eye?

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU180

Red blood cell transfusion dependence and outcome after allogeneic peripheral blood stem cell transplantation in patients with de novo myelodysplastic syndrome (MDS)

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU180

Deferasirox in iron-overloaded patients with transfusion-dependent myelodysplastic syndromes: Results from the large 1-year EPIC study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU180

Summary of the Guidelines for Preventing Opportunistic Infections among Hematopoietic Stem Cell Transplant Recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU180